logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
21/06/2025
Fed's Dale: There are multiple possibilities for the extent to which tariffs are passed on to consumers.
Latest
4 m ago
Henan: The summer planting season is basically over, and the area for autumn crops is stable at more than 76 million mu.
5 m ago
These office "black technology" may have leakage risks, the National Security Department: Don't let video conferences become "live broadcasts"
5 m ago
Market news: Toyota will increase car prices in the United States starting from July.
7 m ago
Novo Nordisk releases early results of clinical trial for the blood sugar-lowering drug Amycretin. Amycretin shows signs of improving blood sugar levels. In the study, Amycretin has shown a weight reduction effect of 24.3%.
7 m ago
Norway and Nord released the early results of the clinical trial for the hypoglycemic drug Amycretin. Amycretin showed signs of improving blood sugar levels. In the study, Amycretin demonstrated a weight loss effect of 24.3%.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.